Cheers mate.
From the EMD announcement:
Zelira will pay Emyria up to $100,000 comprising an upfront fee of $50,000 along with a subscription fee for each patient enrolled in the study, up to a maximum of 100 participants. The initial term of the agreement is for 12 months, with Zelira having an option to extend the term to capture the required minimum of data for each patient.
So $500 per subscription. That seems a bit over the top. The data would want to carry some weight to provide a ROI.
Ann: ZLD Signs Real-World Data Agreement for Zenivol with Emyria, page-20
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ZLD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
73.5¢ |
Change
0.065(9.70%) |
Mkt cap ! $8.340M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 73.5¢ | 67.0¢ | $4.313K | 6.297K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4944 | 72.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 73.5¢ | 14086 | 1 |
View Market Depth
| Last trade - 15.59pm 03/09/2024 (20 minute delay) ? |
| ZLD (ASX) Chart |